Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Tetsuharu Hori"'
Autor:
Taku Kobayashi, Hiroaki Ito, Toshifumi Ashida, Tadashi Yokoyama, Masakazu Nagahori, Tomoki Inaba, Mitsuhiro Shikamura, Takayoshi Yamaguchi, Tetsuharu Hori, Philippe Pinton, Mamoru Watanabe, Toshifumi Hibi
Publikováno v:
Intestinal Research, Vol 19, Iss 4, Pp 448-460 (2021)
Background/Aims A subgroup analysis was conducted in Japanese patients with moderate to severe ulcerative colitis (UC) enrolled in the phase 3 VISIBLE 1 study, which evaluated the safety and efficacy of a new vedolizumab subcutaneous (SC) formulation
Externí odkaz:
https://doaj.org/article/a217aebdf4724fafb49e7e24e2b95de7
Publikováno v:
Intestinal Research, Vol 19, Iss 1, Pp 95-105 (2021)
Background/Aims Vedolizumab is indicated for moderately-to-severely active ulcerative colitis (UC) and Crohn’s disease (CD). Because multiple factors may result in different pharmacokinetics and clinical efficacies, understanding determinants of ve
Externí odkaz:
https://doaj.org/article/9e25be135b40487da6c35a77110ea2ce
Autor:
Satoshi Motoya, Kenji Watanabe, Haruhiko Ogata, Takanori Kanai, Toshiyuki Matsui, Yasuo Suzuki, Mitsuhiro Shikamura, Kenkichi Sugiura, Kazunori Oda, Tetsuharu Hori, Takahiro Araki, Mamoru Watanabe, Toshifumi Hibi
Publikováno v:
PLoS ONE, Vol 14, Iss 4, p e0215491 (2019)
[This corrects the article DOI: 10.1371/journal.pone.0212989.].
Externí odkaz:
https://doaj.org/article/e255e9a903ad467d8476d56d8b0bf85b
Autor:
Satoshi Motoya, Kenji Watanabe, Haruhiko Ogata, Takanori Kanai, Toshiyuki Matsui, Yasuo Suzuki, Mitsuhiro Shikamura, Kenkichi Sugiura, Kazunori Oda, Tetsuharu Hori, Takahiro Araki, Mamoru Watanabe, Toshifumi Hibi
Publikováno v:
PLoS ONE, Vol 14, Iss 2, p e0212989 (2019)
BackgroundVedolizumab safety and efficacy have been established in many populations all over the world, but have never been studied in Japan. We report results from a Phase 3, randomized, double-blind, placebo-controlled study of vedolizumab in Japan
Externí odkaz:
https://doaj.org/article/f73f0908dc8c41e18580be46af9939de
Autor:
Mitsuhiro Shikamura, Yasuo Suzuki, Makoto Naganuma, Toshifumi Hibi, Jovelle Fernandez, Satoshi Motoya, Mamoru Watanabe, Takanori Kanai, Lyann Ursos, Tetsuharu Hori, Kenji Watanabe, Haruhiko Ogata, Shigeru Sakamoto, Toshiyuki Matsui
Publikováno v:
Journal of Gastroenterology and Hepatology. 37:81-88
BACKGROUND AND AIM This study aimed to determine the efficacy and safety of vedolizumab treatment with or without concomitant immunomodulator use in Japanese patients with moderate-to-severe ulcerative colitis. METHODS Among enrolled patients in a ph
Autor:
Lyann Ursos, Shigeru Sakamoto, Mamoru Watanabe, Jovelle Fernandez, Satoshi Motoya, Yasuo Suzuki, Takanori Kanai, Mitsuhiro Shikamura, P. Pinton, Toshifumi Hibi, Masakazu Nagahori, Kenji Watanabe, Tetsuharu Hori, Haruhiko Ogata, Toshiyuki Matsui
Publikováno v:
Digestion
Background and Aim: To evaluate the onset of symptomatic response with vedolizumab in patients with moderate-to-severe ulcerative colitis in Japan. Methods: Patients were randomized to receive vedolizumab 300 mg or placebo at Weeks 0, 2, and 6. Mayo
Autor:
P. Pinton, Tetsuharu Hori, Tadashi Yokoyama, Toshifumi Hibi, Taku Kobayashi, Mamoru Watanabe, Mitsuhiro Shikamura, Masakazu Nagahori, Tomoki Inaba, Takayoshi Yamaguchi, Toshifumi Ashida, Hiroaki Ito
Publikováno v:
Intestinal Research
Intestinal Research, Vol 19, Iss 4, Pp 448-460 (2021)
Intestinal Research, Vol 19, Iss 4, Pp 448-460 (2021)
Background/Aims: A subgroup analysis was conducted in Japanese patients with moderate to severe ulcerative colitis (UC) enrolled in the phase 3 VISIBLE 1 study, which evaluated the safety and efficacy of a new vedolizumab subcutaneous (SC) formulatio
Autor:
Katsuhiko Iwakiri, Eiji Umegaki, Naoki Hiramatsu, Kentarou Kudou, Akira Nishimura, Yuuichi Sakurai, Kiyoshi Ashida, Tetsuharu Hori
Publikováno v:
World Journal of Gastroenterology
AIM To compare vonoprazan 10 and 20 mg vs lansoprazole 15 mg as maintenance therapy in healed erosive esophagitis (EE). METHODS A total of 607 patients aged ≥ 20 years, with endoscopically-confirmed healed EE following 8 wk of treatment with vonopr
Autor:
Tetsuharu Hori, Toshifumi Hibi, Haruhiko Ogata, Kazunori Oda, Satoshi Motoya, Takanori Kanai, Mitsuhiro Shikamura, Yasuo Suzuki, Mamoru Watanabe, Toshiyuki Matsui, Takahiro Araki, Kenji Watanabe, Kenkichi Sugiura
Publikováno v:
PLoS ONE, Vol 14, Iss 2, p e0212989 (2019)
PLoS ONE
PLoS ONE
BackgroundVedolizumab safety and efficacy have been established in many populations all over the world, but have never been studied in Japan. We report results from a Phase 3, randomized, double-blind, placebo-controlled study of vedolizumab in Japan
Autor:
Mamoru Watanabe, Kazunori Oda, Satoshi Motoya, Toshiyuki Matsui, Tetsuharu Hori, Kenkichi Sugiura, Yasuo Suzuki, Toshifumi Hibi, Takahiro Araki, Kenji Watanabe, Haruhiko Ogata, Mitsuhiro Shikamura, Takanori Kanai
Publikováno v:
PLoS ONE, Vol 14, Iss 4, p e0215491 (2019)
[This corrects the article DOI: 10.1371/journal.pone.0212989.].